Jennifer M Yamamoto1, Amy Metcalfe1, Kara A Nerenberg1, Rshmi Khurana1, Alex Chin1, Lois E Donovan2. 1. Departments of Medicine (Yamamoto, Metcalfe, Nerenberg, Donovan), of Obstetrics and Gynecology (Yamamoto, Metcalfe, Nerenberg, Donovan), and of Pathology and Laboratory Medicine (Chin), Cumming School of Medicine, University of Calgary; Alberta Children's Hospital Research Institute (Yamamoto, Metcalfe, Donovan), Calgary, Alta.; and Departments of Medicine and of Obstetrics and Gynecology (Khurana), University of Alberta, Edmonton, Alta. 2. Departments of Medicine (Yamamoto, Metcalfe, Nerenberg, Donovan), of Obstetrics and Gynecology (Yamamoto, Metcalfe, Nerenberg, Donovan), and of Pathology and Laboratory Medicine (Chin), Cumming School of Medicine, University of Calgary; Alberta Children's Hospital Research Institute (Yamamoto, Metcalfe, Donovan), Calgary, Alta.; and Departments of Medicine and of Obstetrics and Gynecology (Khurana), University of Alberta, Edmonton, Alta. lois.donovan@ahs.ca.
Abstract
BACKGROUND: Screening in pregnancy for subclinical hypothyroidism, often defined as thyroid-stimulating hormone (TSH) greater than 2.5 mIU/L or greater than 4.0 mIU/L, is controversial. We determined the frequency and distribution of TSH testing by gestational age, as well as TSH values associated with treatment during pregnancy and the frequency of postpartum continuation of thyroid hormone therapy. METHODS: We performed a retrospective cohort study of pregnancies in Alberta, Canada. We included women without thyroid disease who delivered between October 2014 and September 2017. We used delivery records, physician billings, and pharmacy and laboratory administrative data. Our key outcomes were characteristics of TSH testing and the initiation and continuation of thyroid hormone therapy. We calculated the proportion of pregnancies with thyroid testing and the frequency of each specific thyroid test. RESULTS: Of the 188 490 pregnancies included, 111 522 (59.2%) had at least 1 TSH measurement. The most common time for testing was at gestational week 5 to 6. Thyroid hormone therapy was initiated at a median gestational age of 7 (interquartile range 5-12) weeks. Among women with first TSH measurements of 4.01 to 9.99 mIU/L who were not immediately treated, the repeat TSH measurement was 4.00 mIU/L or below in 67.9% of pregnancies. Thyroid hormone was continued post partum for 44.6% of the women who started therapy during their pregnancy. INTERPRETATION: The findings of our study suggest that current practice patterns may contribute to overdiagnosis of hypothyroidism and overtreatment during pregnancy and post partum.
BACKGROUND: Screening in pregnancy for subclinical hypothyroidism, often defined as thyroid-stimulating hormone (TSH) greater than 2.5 mIU/L or greater than 4.0 mIU/L, is controversial. We determined the frequency and distribution of TSH testing by gestational age, as well as TSH values associated with treatment during pregnancy and the frequency of postpartum continuation of thyroid hormone therapy. METHODS: We performed a retrospective cohort study of pregnancies in Alberta, Canada. We included women without thyroid disease who delivered between October 2014 and September 2017. We used delivery records, physician billings, and pharmacy and laboratory administrative data. Our key outcomes were characteristics of TSH testing and the initiation and continuation of thyroid hormone therapy. We calculated the proportion of pregnancies with thyroid testing and the frequency of each specific thyroid test. RESULTS: Of the 188 490 pregnancies included, 111 522 (59.2%) had at least 1 TSH measurement. The most common time for testing was at gestational week 5 to 6. Thyroid hormone therapy was initiated at a median gestational age of 7 (interquartile range 5-12) weeks. Among women with first TSH measurements of 4.01 to 9.99 mIU/L who were not immediately treated, the repeat TSH measurement was 4.00 mIU/L or below in 67.9% of pregnancies. Thyroid hormone was continued post partum for 44.6% of the women who started therapy during their pregnancy. INTERPRETATION: The findings of our study suggest that current practice patterns may contribute to overdiagnosis of hypothyroidism and overtreatment during pregnancy and post partum.
Authors: Spyridoula Maraka; Raphael Mwangi; Xiaoxi Yao; Lindsey R Sangaralingham; Naykky M Singh Ospina; Derek T O'Keeffe; Rene Rodriguez-Gutierrez; Marius N Stan; Juan P Brito; Victor M Montori; Rozalina G McCoy Journal: J Clin Endocrinol Metab Date: 2019-04-24 Impact factor: 5.958
Authors: Brian M Casey; Elizabeth A Thom; Alan M Peaceman; Michael W Varner; Yoram Sorokin; Deborah G Hirtz; Uma M Reddy; Ronald J Wapner; John M Thorp; George Saade; Alan T N Tita; Dwight J Rouse; Baha Sibai; Jay D Iams; Brian M Mercer; Jorge Tolosa; Steve N Caritis; J Peter VanDorsten Journal: N Engl J Med Date: 2017-03-02 Impact factor: 91.245
Authors: Leslie De Groot; Marcos Abalovich; Erik K Alexander; Nobuyuki Amino; Linda Barbour; Rhoda H Cobin; Creswell J Eastman; John H Lazarus; Dominique Luton; Susan J Mandel; Jorge Mestman; Joanne Rovet; Scott Sullivan Journal: J Clin Endocrinol Metab Date: 2012-08 Impact factor: 5.958
Authors: Charlotte Hales; Peter N Taylor; Sue Channon; Kirsten McEwan; Anita Thapar; Kate Langley; Ilaria Muller; Mohd S Draman; Colin Dayan; John W Gregory; Onyebuchi Okosieme; John H Lazarus; D Aled Rees; Marian Ludgate Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958
Authors: Mihaela Țarnă; Luminița Nicoleta Cima; Anca Maria Panaitescu; Carmen Sorina Martin; Anca Elena Sîrbu; Carmen Gabriela Barbu; Bogdan Pavel; Andreea Nicoleta Șerbănică; Simona Fica Journal: Medicina (Kaunas) Date: 2022-08-18 Impact factor: 2.948